Cue Biopharma, Inc. (CUE)

NCM – Real vaqt narxi. Valyuta: USD

29.26

-2.06 (-6.58%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company's 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

22.04.2026

Cue Biopharma Announces 1-for-30 Reverse Stock Split

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will implement a 1-for-30 reverse stock split of the issued shares of the company's common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026.

10.04.2026

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

The biopharmaceutical company is developing injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body.

08.04.2026

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage memory T cell subsets to deplete pathogenic B cells for the potential treatment of autoimmune and inflammatory diseases, today announced that it will receive a $7.5 million preclinical milestone payment under its collaboration and license agreement with Boehringer Ingelheim following Boehringer Ingelheim's selection and approval of its first compound for lead optimization. The Company expects to receive the payment in May 2026.

07.04.2026

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

27.03.2026

Cue Biopharma Announces CEO Transition

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, an industry veteran who has served as Cue Biopharma's chief financial and business officer since February 2026 and previously as Cue Biopharma's chief business officer from September 2024 until February 2026, has been appointed interim president and chief executive officer (CEO). Usman Azam has stepped down as president and CEO and as a director, effective March 26, 2026.

26.03.2026

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR

Videolar

No Data

There is no data to display

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

27.03.2026

Cue Biopharma, Inc. (CUE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cue Biopharma, Inc. (CUE)

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma Announces CEO Transition

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Videolar

No Data

Press-relizlar

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma Announces CEO Transition

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma Announces CEO Transition

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Videolar

No Data

Press-relizlar

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma Announces CEO Transition

Search stocks

Cue Biopharma, Inc. (CUE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cue Biopharma, Inc. (CUE)

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma Announces CEO Transition

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Videolar

No Data

Press-relizlar

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma Announces CEO Transition

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma Announces CEO Transition

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Videolar

No Data

Press-relizlar

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma Announces CEO Transition